Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Covington
Fuji
Mallinckrodt
Express Scripts
Chinese Patent Office
Deloitte
Cerilliant
Teva

Generated: January 23, 2018

DrugPatentWatch Database Preview

ASACOL Drug Profile

« Back to Dashboard

Which patents cover Asacol, and when can generic versions of Asacol launch?

Asacol is a drug marketed by Apil and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in ASACOL is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
Drug patent expirations by year for ASACOL
Pharmacology for ASACOL
Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Medical Subject Heading (MeSH) Categories for ASACOL

US Patents and Regulatory Information for ASACOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil ASACOL mesalamine TABLET, DELAYED RELEASE;ORAL 019651-001 Jan 31, 1992 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Apil ASACOL HD mesalamine TABLET, DELAYED RELEASE;ORAL 021830-001 May 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Apil ASACOL HD mesalamine TABLET, DELAYED RELEASE;ORAL 021830-001 May 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Apil ASACOL HD mesalamine TABLET, DELAYED RELEASE;ORAL 021830-001 May 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ASACOL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Delayed-release Tablets 800 mg ➤ Subscribe 7/13/2011
➤ Subscribe Delayed-release Tablets 400 mg ➤ Subscribe 6/22/2007

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Accenture
US Army
McKesson
Colorcon
Citi
Teva
Deloitte
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot